Table 1 Clinical characteristics of the study groups

From: Serum fibroblast growth factor 21 in human obesity: regulation by insulin infusion and relationship with glucose and lipid oxidation

 

Lean group (n=42)

Obese group (n=42)

Age (years)

24.24±4.56

26.05±6.80

BMI (kg m−2)

22.16±2.01

30.85±4.61*

Waist (cm)

75.34±7.58

97.08±13.54*

Percent body fat

22.65±6.69

37.54±8.44*

Fasting glucose (mg dl−1)

81.23±7.39

84.54±8.50

Postload glucose (mg dl−1)

78.26±16.44

94.18±23.69*

Fasting insulin (μIU ml−1)

9.98±4.95

16.33±8.71*

Postload insulin (μIU ml−1)

29.43±19.51

67.75±62.13*

Cholesterol (mg dl−1)

174.89±29.29

172.25±35.06

Triglycerides (mg dl−1)

73.75±29.81

129.72±142.55*

HDL–cholesterol (mg dl−1)

61.73±12.46

56.35±10.30*

LDL–cholesterol (mg dl−1)

96.94±30.36

91.56±29.83

Fasting FFA (mmol l−1)

0.52±0.26

0.63±0.29

  1. Abbreviations: FFA, free fatty acids; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
  2. *P<0.05 vs lean subjects
Back to article page